🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Lee Ainslie’s NAMS Holdings & Trades

First Buy
Q4 2024
Duration Held
6 Quarters
Largest Add
Q2 2025
+982,405 Shares
Current Position
2.19 M Shares
$69.99 M Value

Lee Ainslie's NAMS Position Overview

Lee Ainslie (via Maverick Capital LTD) currently holds 2.19 M shares of NewAmsterdam Pharma Company N.V. (NAMS) worth $69.99 M, representing 0.81% of the portfolio. First purchased in 2024-Q4, this short-term holding has been held for 6 quarters.

Based on 13F filings, Lee Ainslie has maintained this position in NAMS for several quarters, showing initial confidence in the investment. Largest addition occurred in Q2 2025, adding 982,405 shares. Largest reduction occurred in Q3 2025, reducing 27,127 shares.

Analysis based on 13F filings available since 2013 Q2

Lee Ainslie's NewAmsterdam Pharma Company NV (NAMS) Holding Value Over Time

Track share changes against reported price movement

Quarterly NewAmsterdam Pharma Company NV (NAMS) Trades by Lee Ainslie

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +292,176 Add 15.42% 2.19 M $32.01
Q4 2025 +389,479 Add 25.88% 1.89 M $35.08
Q3 2025 -27,127 Reduce 1.77% 1.5 M $28.44
Q2 2025 +982,405 Add 178.79% 1.53 M $18.11
Q1 2025 +199,464 Add 56.99% 549,469 $20.47
Q4 2024 +350,005 New Buy 350,005 $25.70

Lee Ainslie's NewAmsterdam Pharma Company NV Investment FAQs

Lee Ainslie first purchased NewAmsterdam Pharma Company N.V. (NAMS) in Q4 2024, acquiring 350,005 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Lee Ainslie has held NewAmsterdam Pharma Company N.V. (NAMS) for 6 quarters since Q4 2024.

Lee Ainslie's largest addition to NewAmsterdam Pharma Company N.V. (NAMS) was in Q2 2025, adding 1,531,874 shares worth $27.74 M.

According to the latest 13F filing for Q1 2026, Lee Ainslie's firm, Maverick Capital LTD, owns 2,186,402 shares of NewAmsterdam Pharma Company N.V. (NAMS), valued at approximately $69.99 M.

As of the Q1 2026 filing, NewAmsterdam Pharma Company N.V. (NAMS) represents approximately 0.81% of Lee Ainslie's publicly disclosed stock portfolio, making it one of their key holdings.

Lee Ainslie's peak holding in NewAmsterdam Pharma Company N.V. (NAMS) was 2,186,402 shares, as reported at the end of Q1 2026.